|
1
|
Zhou C: Lung cancer molecular epidemiology
in China: Recent trends. Transl Lung Cancer Res. 3:270–279.
2014.PubMed/NCBI
|
|
2
|
Land SR, Liu Q, Wickerham DL, Costantino
JP and Ganz PA: Cigarette smoking, physical activity, and alcohol
consumption as predictors of cancer incidence among women at high
risk of breast cancer in the NSABP P-1 trial. Cancer Epidemiol
Biomarkers Prev. 23:823–832. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou QH, Fan YG, Bu H, Wang Y, Wu N, Huang
YC, Wang G, Wang XY and Qiao YL: China national lung cancer
screening guideline with low-dose computed tomography (2015
version). Thorac Cancer. 6:812–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motallebnezhad M, Jadidi-Niaragh F,
Qamsari ES, Bagheri S, Gharibi T and Yousefi M: The immunobiology
of myeloid-derived suppressor cells in cancer. Tumour Biol.
37:1387–1406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qu P, Wang LZ and Lin PC: Expansion and
functions of myeloid-derived suppressor cells in the tumor
microenvironment. Cancer Lett. 380:253–256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ochando J, Conde P and Bronte V:
Monocyte-derived suppressor cells in transplantation. Curr
Transplant Rep. 2:176–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haile LA, von Wasielewski R,
Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, Buer J,
Liblau R, Manns MP, Korangy F and Greten TF: Myeloid-derived
suppressor cells in inflammatory bowel disease: A new
immunoregulatory pathway. Gastroenterology. 135:871–881, 881.e1-e5.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Detterbeck FC, Postmus PE and Tanoue LT:
The stage classification of lung cancer: Diagnosis and management
of lung cancer, III ed: American College of Chest Physicians
evidence-based clinical practice guidelines. Chest. 143 5
Suppl:e191S–e210S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jett JR, Schild SE, Kesler KA and
Kalemkerian GP: Treatment of small cell lung cancer: Diagnosis and
management of lung cancer, 3rd ed: American College of Chest
Physicians evidence-based clinical practice guidelines. Chest. 143
5 Suppl:e400S–e419S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Travis WD, Brambilla E and Riely GJ: New
pathologic classification of lung cancer: Relevance for clinical
practice and clinical trials. J Clin Oncol. 31:992–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang G, Huang H, Zhu Y, Yu G, Gao X, Xu
Y, Liu C, Hou J and Zhang X: A novel subset of
B7-H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are
associated with progression of human NSCLC. Oncoimmunology.
4:e9771642015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simon AK, Hollander GA and McMichael A:
Evolution of the immune system in humans from infancy to old age.
Proc Biol Sci. 282:pp. 201430852015; View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alizadeh D and Larmonier N:
Chemotherapeutic targeting of cancer-induced immunosuppressive
cells. Cancer Res. 74:2663–2668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Keskinov AA and Shurin MR: Myeloid
regulatory cells in tumor spreading and metastasis. Immunobiology.
220:236–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Laborde RR, Lin Y, Gustafson MP, Bulur PA
and Dietz AB: Cancer vaccines in the world of immune suppressive
monocytes (CD14(+)HLA-DR (lo/neg) cells): The gateway to improved
responses. Front Immunol. 5:1472014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bruchard M and Ghiringhelli F: Impact of
chemotherapies on immunosuppression and discovery of new
therapeutic targets. Bull Cancer. 101:605–607. 2014.(In French).
PubMed/NCBI
|
|
17
|
Kennedy DE and Knight KL: Inhibition of B
lymphopoiesis by adipocytes and IL-1-producing myeloid-derived
suppressor cells. J Immunol. 195:2666–2674. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Michaud HA, Eliaou JF, Lafont V, Bonnefoy
N and Gros L: Tumor antigen-targeting monoclonal antibody-based
immunotherapy: Orchestrating combined strategies for the
development of long-term antitumor immunity. Oncoimmunology.
3:e9556842014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Albeituni SH, Ding C, Liu M, Hu X, Luo F,
Kloecker G, Bousamra M II, Zhang HG and Yan J: Yeast-derived
particulate beta-glucan treatment subverts the suppression of
myeloid-derived suppressor cells (MDSC) by inducing
polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation
to APC in cancer. J Immunol. 196:2167–2180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koinis F, Vetsika EK, Aggouraki D,
Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulias V and
Kotsakis A: Effect of first-line treatment on myeloid-derived
suppressor cells' subpopulations in the peripheral blood of
patients with non-small cell lung cancer. J Thorac Oncol.
11:1263–1272. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang A, Zhang B, Wang B, Zhang F, Fan KX
and Guo YJ: Increased CD14(+)HLA-DR(−/low) myeloid-derived
suppressor cells correlate with extrathoracic metastasis and poor
response to chemotherapy in non-small cell lung cancer patients.
Cancer Immunol Immunother. 62:1439–1451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Umansky V, Sevko A, Gebhardt C and Utikal
J: Myeloid-derived suppressor cells in malignant melanoma. J Dtsch
Dermatol Ges. 12:1021–1027. 2014.(In English, German). View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Albeituni SH, Ding C, Liu M, Hu X, Luo F,
Kloecker G, Bousamra M II, Zhang HG and Yan J: Yeast-derived
particulate β-glucan treatment subverts the suppression of
myeloid-derived suppressor cells (MDSC) by inducing
polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation
to APC in cancer. J Immunol. 196:2167–2180. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang A, Zhang B, Wang B, Zhang F, Fan KX
and Guo YJ: Increased CD14(+)HLA-DR(−/low) myeloid-derived
suppressor cells correlate with extrathoracic metastasis and poor
response to chemotherapy in non-small cell lung cancer patients.
Cancer Immunol Immunother. 62:1439–1451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang J, Guo W and Liang X: Phenotypes,
accumulation, and functions of myeloid-derived suppressor cells and
associated treatment strategies in cancer patients. Hum Immunol.
75:1128–1137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gutknecht MF and Bouton AH: Functional
significance of mononuclear phagocyte populations generated through
adult hematopoiesis. J Leukoc Biol. 96:969–980. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yin Y, Huang X, Lynn KD and Thorpe PE:
Phosphatidylserine-targeting antibody induces M1 macrophage
polarization and promotes myeloid-derived suppressor cell
differentiation. Cancer Immunol Res. 1:256–268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du Four S, Maenhout SK, Niclou SP,
Thielemans K, Neyns B and Aerts JL: Combined VEGFR and CTLA-4
blockade increases the antigen-presenting function of intratumoral
DCs and reduces the suppressive capacity of intratumoral MDSCs. Am
J Cancer Res. 6:2514–2531. 2016.PubMed/NCBI
|
|
29
|
Liu J, Zhou Y, Huang Q and Qiu L:
CD14+HLA-DRlow/− expression: A novel prognostic factor in chronic
lymphocytic leukemia. Oncol Lett. 9:1167–1172. 2015.PubMed/NCBI
|
|
30
|
Shi G, Wang H and Zhuang X:
Myeloid-derived suppressor cells enhance the expression of
melanoma-associated antigen A4 in a Lewis lung cancer murine model.
Oncol Lett. 11:809–816. 2016.PubMed/NCBI
|
|
31
|
Draghiciu O, Lubbers J, Nijman HW and
Daemen T: Myeloid derived suppressor cells-An overview of combat
strategies to increase immunotherapy efficacy. Oncoimmunology.
4:e9548292015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ostrand-Rosenberg S: Myeloid-derived
suppressor cells: More mechanisms for inhibiting antitumor
immunity. Cancer Immunol Immunother. 59:1593–1600. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Solito S, Marigo I, Pinton L, Damuzzo V,
Mandruzzato S and Bronte V: Myeloid-derived suppressor cell
heterogeneity in human cancers. Ann N Y Acad Sci. 1319:47–65. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de Sanctis F, Solito S, Ugel S, Molon B,
Bronte V and Marigo I: MDSCs in cancer: Conceiving new prognostic
and therapeutic targets. Biochim Biophys Acta. 1865:35–48.
2016.PubMed/NCBI
|
